3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Neoplasm Metastasis
10
Carcinoma, Medullary
10
Thyroid Neoplasms
5
Lung Neoplasms
5
Prostatic Neoplasms
3
Neoplasms
3
Adenocarcinoma
3
Familial medullary thyroid carcinoma
2
Colorectal Neoplasms
2
Carcinoma, Squamous Cell
2
Breast Neoplasms
2
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Mesothelioma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Differentiated Thyroid Cancer
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Large Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Biliary Tract Neoplasms
1
Aggression
1
Advanced Breast Cancer
1
Interventions
vandetanib
1
Surgical Procedures, Operative
1
Pemetrexed
1
Gemcitabine
1
Darbepoetin alfa
1
Cisplatin
1
Cdc25C phosphatase (211-221)
1
Catheters, Indwelling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pleural Effusion
×
vandetanib
×
Clear all
NCT00753714
2016-10-17
ZELIG
Sanofi
Phase 2
Completed
124 enrolled
11 charts